Freeline Therapeutics Holdings plc

Freeline Therapeutics Holdings plc (FRLN) priced its initial public offering on Aug 10, 2020 at $18.00 per ADS, raising $158.8M, and listed on Nasdaq Global Select. At the IPO price its market capitalization was about $625.4M. J.P. Morgan was lead-left underwriter, joined by Morgan Stanley, Evercore ISI and Wedbush. Davis Polk advised the company and Goodwin Procter advised the underwriters.

Freeline Therapeutics Holdings plc is a clinical-stage gene therapy company developing systemic AAV-based treatments aimed at one-time functional cures for inherited, debilitating monogenic diseases. It is fully integrated across research, manufacturing and clinical development, with two clinical programs and two late-stage preclinical candidates.

Status

IPO

Ticker

FRLN

Exchange

Nasdaq Global Select

Priced

Aug 10, 2020

IPO price

$18.00 per ADS

Raised

$158.8M

Market cap at IPO price

$625.4M

First filed

Jul 17, 2020

Underwriters

J.P. Morgan, Morgan Stanley, Evercore ISI and Wedbush

Company counsel

Davis Polk

Underwriters' counsel

Goodwin Procter

Sector

Biotech & pharma

Country / state

United Kingdom

Market cap at IPO price = shares outstanding after the offering (all classes, before the over-allotment option) × the IPO price, from the final prospectus.